FDA policy pivot unlocks rare disease assets
The FDA's recent policy updates permitting alternative trial designs over placebo comparisons have revitalized valuations and deal activity for clinical-stage rare disease biotechs.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.